Rextol

Quick links to important sections

Rextol

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rextol

Property Description
Active ingredient Paricalcitol
Form Capsule (Oral), Solution (Intravenous)
Pharmacological class Selective Vitamin D Receptor (VDR) Activator
General Purpose PTH (Parathyroid Hormone) Regulation
Origin Synthetic Analog

What Type of Medicine is Rextol? (Classification and Origin)

Rextol is the product name for the active ingredient Paricalcitol, a prescription-only medicine classified pharmacologically as a Selective Vitamin D Receptor (VDR) Activator. Paricalcitol is a synthetic analog, meaning it is a man-made compound chemically derived from Vitamin D2. The compound is designed for targeted action on specific receptors. It is a derivative that binds to the Vitamin D receptor, resulting in the inhibition of Parathyroid Hormone (PTH) secretion. This means the drug is chemically designed to specifically regulate a key hormone in the body, distinguishing it as a modern, second-generation Vitamin D compound.

Rextol's Composition and Available Forms (Identity and Composition)

Rextol is available as a single-ingredient drug in two distinct pharmaceutical forms: soft gelatin capsules for oral use and a solution for injection for intravenous (IV) administration. The composition differs depending on the form; for example, the solution for injection contains Paricalcitol alongside excipients such as alcohol and propylene glycol to facilitate stability and proper IV delivery. Paricalcitol acts to reduce PTH concentrations. Its selective affinity for the VDR in parathyroid tissue is a primary differentiating factor compared to older vitamin D agents.

General Purpose: How it Regulates Hormonal Balance (Mechanism and Purpose)

The general function of Rextol is to directly assist in the management of Parathyroid Hormone (PTH) levels by engaging the body’s regulatory system. Rextol’s selective action targets the VDR on parathyroid gland cells. This binding sends a biological signal that controls the rate at which these glands synthesize and secrete PTH. The overall purpose is to help restore a more appropriate and stable hormonal balance, addressing the imbalance that frequently arises when the kidneys are unable to convert Vitamin D to its active form efficiently. This regulatory action is a mainstay approach in individuals requiring hormonal support.

What side effects are possible with Rextol?

Possible side effects and safety information

The official safety profile for Rextol (Paricalcitol) describes adverse reactions primarily categorized by frequency and the body system affected. All documented information is based strictly on regulatory prescribing documents, such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).

Adverse Reaction Scope

Category Description
Key adverse reaction categories The most frequent documented safety characteristics involve Metabolism and Nutrition Disorders, often resulting in changes to calcium and phosphorus levels. Gastrointestinal and Nervous System disorders are also commonly reported System-Organ Classes.
Common side effects Officially classified effects frequently reported include Hypercalcemia (elevated calcium levels), Nausea, Vomiting, Diarrhea, Edema, and Headache.
Serious adverse reactions Documented serious adverse reactions include Severe Hypercalcemia (which may lead to cardiac arrhythmias and seizures), Sepsis, Pneumonia, and rare Hypersensitivity Reactions such as Angioedema and Laryngeal Oedema.
Safety-related restrictions The medicine is officially contraindicated in patients with pre-existing evidence of Hypercalcemia or Vitamin D toxicity. Caution is required when used concomitantly with strong CYP3A inhibitors or Digitalis compounds.
Population-specific safety Safety and efficacy are not established in the pediatric population under 10 years of age. For patients with Hepatic Impairment, no dose adjustment is required for mild to moderate conditions, but there is no regulatory experience documented for severe impairment.
Exposure-related patterns Frequent monitoring of serum calcium, phosphorus, and Parathyroid Hormone (PTH) is mandated, particularly during the initial dosing phase and following any dose adjustments.

Connection to the overall safety profile

The regulatory safety documentation defines the profile by establishing the risk of metabolic disruption as the primary concern, requiring strict monitoring during initiation and adjustment. The profile also clearly outlines absolute restrictions based on pre-existing metabolic conditions and documents the potential for less common, but serious, reactions affecting multiple organ systems.

Overdose and Emergency Response

The official regulatory profile for Rextol (Paricalcitol) overdosage centers on the risk of hypercalcemia, or abnormally high serum calcium levels, which is the documented cause of systemic toxicity and can lead to signs of Vitamin D intoxication.

Manifestations and Risks Regulator-Mandated Action
Documented Manifestations: Early symptoms of intoxication may include weakness, headache, dry mouth, metallic taste, muscle pain, and vomiting. Late symptoms documented include anorexia, weight loss, pancreatitis, and visual disturbances.
Dose Adjustment: If clinically significant hypercalcemia develops, the Rextol dose must be immediately reduced or interrupted as an initial procedural step.
Severe Outcomes: Acute hypercalcemia may exacerbate tendencies for cardiac arrhythmias and seizures. Chronic over-administration carries the risk of generalized vascular calcification and other soft-tissue calcification.
Urgent Medical Attention: Progressive hypercalcemia due to overdosage may be so severe as to require emergency attention. Serum calcium and phosphorus levels must be monitored closely during management.

The most serious risk in overdose is the potential for acute hypercalcemia to cause severe systemic complications, including those affecting the heart and central nervous system. The official labeling confirms that management is supportive and is constrained by the lack of a specific antidote. All sources of Vitamin D and calcium intake should be withheld when overdosage is suspected.

Therapeutic Uses of Rextol

Rextol is commonly used to help with the management of a condition characterized by periods of heightened symptoms known as secondary hyperparathyroidism (HPT) in chronic renal failure patients on hemodialysis. The medication is used to address the symptoms related to systemic imbalance that often accompany this condition.

The therapeutic use of Rextol is considered relevant for easing symptoms linked to organ-specific functional stress. Its primary therapeutic domain involves supportive assistance with secondary HPT in patients with chronic kidney failure who require hemodialysis. This medication plays a role in managing systemic factors linked to the disease, which may assist with maintaining functional stability.

The application of Rextol is often used during phases when symptoms become more noticeable and when supportive symptom management is appropriate. This support helps maintain a sense of stability when symptoms are more noticeable, and supports general well-being during symptomatic phases. “It contributes to easing the overall symptom load for patients requiring additional symptomatic assistance.”

Relief for Symptoms related to systemic imbalance

Regulatory References

  1. Official Product Characteristics for Rextol

Eligibility and Restrictions for Use

The eligibility profile for Rextol (Paricalcitol) is strictly defined by regulatory authorities, focusing on population-specific conditions and contraindications.

Official Contraindications

The medicine is contraindicated and must not be used in patients with existing Hypercalcemia (high calcium levels in the blood) or evidence of Vitamin D toxicity. Use is also prohibited for individuals with a known hypersensitivity to the active ingredient Paricalcitol or any component of the formulation.

Approved and Restricted Populations

Rextol is officially indicated for adults with secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD). Eligibility is also established for specific pediatric groups: the intravenous formulation is approved for patients 5 years of age and older, while the oral capsule is approved for patients 10 years of age and older. Use is not established in children younger than these respective age thresholds.

Regarding physiological status, Rextol is classified as Pregnancy Category C, and breastfeeding is not recommended during treatment. Furthermore, the medicine has not been studied in patients with severe hepatic impairment, limiting eligibility for that group. Caution is required for patients receiving Digitalis compounds, due to risks related to hypercalcemia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents outline specific interaction patterns for Rextol (Paricalcitol) that primarily affect drug exposure and risk of elevated calcium levels. These interactions are categorized as pharmacokinetic (PK) or pharmacodynamic (PD) based on their official description.

Documented Pharmacokinetic Interactions

Co-administration with strong CYP3A inhibitors, such as Ketoconazole, increases Rextol's systemic exposure (AUC and Cmax) by impeding its metabolism. Conversely, the intestinal absorption of the oral capsule is officially documented to be reduced by bile acid sequestrants (e.g., Cholestyramine) and mineral oil. To mitigate this absorption loss, the regulatory label mandates that oral Rextol must be administered more than one hour before OR four to six hours after these agents.

Documented Pharmacodynamic Interactions and Restrictions

The primary PD interaction involves the risk of hypercalcemia (elevated calcium levels). Because of this additive effect, prescription-based doses of Vitamin D and its derivatives must be withheld during Rextol treatment. Furthermore, combining Rextol with high-dose calcium-containing preparations or Thiazide diuretics increases the risk of hypercalcemia. Separately, the toxicity of Digitalis compounds (cardiac glycosides) may be potentiated if Rextol causes hypercalcemia. Chronic use of aluminum-containing preparations is also restricted due to the potential for increased systemic aluminum levels and toxicity.

Mechanism of Action

Selective Activation of the Nuclear Vitamin D Receptor (VDR)

Rextol functions as a Selective Vitamin D Receptor (VDR) Activator, binding to this nuclear transcription factor primarily within the parathyroid glands. This molecular interaction initiates a gene transcription cascade that targets the DNA sequence responsible for synthesizing Parathyroid Hormone (PTH). The drug's action directly leads to the suppression of PTH production, and this modulation influences the endocrine system's homeostatic feedback loop.

Differential Modulation of Mineral Homeostasis

The mechanism is defined by its relative selectivity. Rextol exhibits attenuated activity on VDRs located in non-parathyroid tissues, such as the intestine. This differential activity leads to a reduced stimulation of calcium and phosphate absorption from the gut. The targeted influence on the PTH pathway leads to the establishment of a more appropriate mineral equilibrium. This transcription-regulating mechanism contributes to the modulation of the body’s endocrine response and shapes the drug’s overall physiological effect profile.

Dosage and Administration Information

How Rextol (Paricalcitol) Is Used: Administration Overview

This section describes the principles for using Rextol, focusing on the administration methods for this medication.


Administration Scope

Instruction Detail
Route of administration Oral (capsule) and Intravenous (IV) injection (solution).
Dosing schedule (General) Typically administered three times a week (IV route, or oral for certain CKD stages) or once daily (oral route).
Timing in relation to meals Oral capsules may be taken without regard to food.
Age-group rules IV use is for pediatric patients 5 years of age and older on hemodialysis. No dose adjustment is required for older adults.

Procedural Structure and Dosing Logic

Therapy with Rextol is structured around a calculated approach rather than a fixed standard dose. The initial dose is calculated based on the patient's current intact Parathyroid Hormone (iPTH) level or body weight (for IV use).

Procedural steps include:

  • Initial Dose Calculation: The starting dose is derived using a specific formula or weight-based metric based on the patient's pre-treatment iPTH levels, rather than a standard amount.
  • Administration Protocol: The IV solution is administered as an undiluted bolus injection through the hemodialysis vascular access port during the dialysis session. The oral form is taken as a capsule.
  • Titration: The administered dose involves adjustments at 2- to 4-week intervals based on monitoring of the patient's iPTH, calcium, and phosphorus laboratory values.

This use protocol ensures the drug's delivery method and dosing are individualized based on ongoing physiological response.

Recent Clinical Evidence

Research evidence / Overview of studies for Rextol


Evidence for Secondary Hyperparathyroidism in Dialysis Patients (CKD Stage 5)

The primary research for Rextol (Paricalcitol) was evaluated in adults and children with advanced Chronic Kidney Disease (CKD Stage 5) who receive regular hemodialysis or peritoneal dialysis. Research was studied for the regulation of parathyroid hormone (PTH) levels, which is a common complication in this population. The core evidence base includes multiple Randomized Controlled Trials (RCTs), alongside systematic reviews that combine and analyze data from many of these trials.

Structure of Primary Evidence

In these short-term studies, researchers monitored several key outcomes related to systemic or functional imbalance, focusing mainly on changes in intact Parathyroid Hormone (iPTH) levels. These trials examined the proportion of patients who achieved a pre-defined reduction in iPTH over periods typically lasting up to 24 weeks. Studies also closely monitored other blood markers, including calcium and phosphorus levels. Research highlights changes measured during the study period where iPTH levels were among the outcomes related to systemic or functional imbalance observed. Comparative evidence is lacking in some areas, but certain trials examined the incidence of elevated serum calcium compared to other therapies.


Evidence for Secondary Hyperparathyroidism in Non-Dialysis Patients (CKD Stages 3 and 4)

Research has also explored the role of Rextol in individuals with earlier-stage kidney problems (CKD Stages 3 and 4) who are not yet undergoing dialysis. This evidence was evaluated in a series of controlled trials, often lasting around 24 weeks. The primary focus of these studies was also on outcomes related to systemic or functional imbalance, using iPTH reduction as the main measurement. Compared to a placebo, these studies data show patterns related to iPTH levels. However, comparative evidence is lacking against all other similar medicines in this specific non-dialysis population.


Long-Term Evidence and Durability of Study Findings

Evidence regarding long-term outcomes for patients was studied for extended periods in observational research and long-term follow-up trials, sometimes extending up to four years. This research examined the stability of key blood markers and, in some studies, outcomes related to mortality. However, large, long-term effects are not fully established by prospective, randomized controlled trials specifically designed and powered to examine clinical outcomes like bone fracture rates or cardiovascular events.

Key Studies & References

  1. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD–Mineral and Bone Disorder (CKD-MBD)
  2. Summary of Product Characteristics (SmPC) for Zemplar (Paricalcitol)

Frequently Asked Questions (FAQ)

Common questions about Rextol (FAQ)

Q: Is Rextol a type of painkiller or something else?

A: Rextol is not classified as a painkiller (analgesic). It is a Selective Vitamin D Receptor Activator. Its primary function is to help manage and regulate the levels of Parathyroid Hormone (PTH) in the body, particularly for individuals with Chronic Kidney Disease.

Q: Does Rextol cause weight gain or loss?

A: Regulatory documents indicate that both weight loss (or decreased weight) and weight gain have been reported as uncommon side effects in clinical trials. If any persistent weight change is noticed, it is important to discuss this with a healthcare provider.

Q: Can Rextol affect my sleep schedule?

A: Official product information reports that insomnia (difficulty sleeping) is listed as a common side effect of Rextol. If you experience persistent changes to your sleep schedule, these effects should be discussed with a healthcare provider.

Q: Can Rextol cause stomach problems?

A: Gastrointestinal disorders are listed among the commonly reported side effects. These problems can include symptoms such as nausea, vomiting, diarrhea, constipation, and general stomach discomfort.

Q: Will taking Rextol affect my ability to drive or operate machinery?

A: The official product information states that Rextol may cause side effects such as dizziness or confusion. Due to the potential for these effects, individuals should assess their reaction to the medication before driving or operating machinery.

Q: Is there a generic version of Rextol available?

A: Yes. Rextol is the brand name for the active ingredient Paricalcitol, which is available in generic form.

Q: Is Rextol safe for people with kidney or liver issues?

A: The medicine is indicated for use in patients with secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD). Regarding the liver, no dose adjustment is required for patients with mild to moderate liver impairment. However, safety data for people with severe liver impairment is not established in regulatory documents.

Q: Is it possible to be allergic to Rextol?

A: Yes. The medicine is contraindicated (must not be used) if a patient has a known hypersensitivity or allergy to the active ingredient Paricalcitol or any component of the formulation. Rare, serious allergic reactions, such as angioedema, have been reported.

Q: Does Rextol affect blood pressure or heart rate?

A: Adverse reaction reports include changes in blood pressure, specifically both hypertension (high blood pressure) and hypotension (low blood pressure). Additionally, palpitations and an irregular or fast heartbeat have also been reported as possible side effects.

Q: Is Rextol effective for all stages of the condition it treats?

A: Rextol is officially indicated for secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD). Its use is supported by evidence from clinical trials conducted across CKD Stages 3, 4, and 5.

Q: What is the general success rate of Rextol in clinical trials?

A: Clinical trials reported that a number of subjects achieved a pre-defined reduction in Parathyroid Hormone (PTH) levels. This reduction, such as 30% or 50% from the baseline level, was monitored over the study period.

Q: Are there any known long-term side effects associated with Rextol use?

A: The primary safety concern highlighted in official documents is the risk of metabolic disruption, particularly severe hypercalcemia (extremely high calcium), which can have long-term consequences if not managed. Chronic use of aluminum-containing preparations is also restricted due to the potential for increased systemic aluminum toxicity.

Q: Does Rextol affect fertility or hormones?

A: Rextol is a synthetic Vitamin D analog that regulates Parathyroid Hormone (PTH). It is classified as Pregnancy Category C and is not recommended for use during breastfeeding. Official regulatory documents do not extensively detail effects on fertility.

Q: Is it true that Rextol can cause weird dreams?

A: Nightmares have been reported as a less common side effect in the official safety data derived from clinical trials.

Q: How quickly does Rextol start to work after taking it?

A: Following oral administration, the medicine reaches its highest concentration in the blood after approximately three hours. Achieving the desired therapeutic effect, which involves regulating PTH, requires dose adjustments that are based on monitoring blood test results at prescribed intervals.

Q: Will I feel different right away when I start taking Rextol?

A: Some common side effects, such as headache or nausea, may be experienced soon after administration. However, the medicine's primary goal—PTH regulation—is a gradual process tracked over time via laboratory blood tests, not necessarily by immediate physical sensation.

Q: What are the most common side effects people complain about with Rextol?

A: According to official safety documentation, the most frequently reported side effects include hypercalcemia (high calcium levels), nausea, vomiting, diarrhea, swelling (edema), and headache.

Q: Is it normal to feel a bit dizzy when you first start Rextol?

A: Dizziness is listed as a reported side effect of the medicine. If this symptom occurs, its potential effect on daily activities, particularly those requiring attention, should be considered.

Q: Are there any foods or drinks I need to avoid while on Rextol?

A: The oral capsule may generally be taken without regard to food. However, official warnings require caution with or avoidance of high-dose calcium-containing preparations, Vitamin D supplements, and certain diuretics due to the risk of high calcium levels. Some patient information advises avoiding grapefruit and grapefruit juice.

Q: Does Rextol interact with herbal supplements like St. John's Wort?

A: Rextol interacts with substances that influence the CYP3A enzyme, such as strong CYP3A inhibitors. Herbal products known to affect this enzyme, like St. John's Wort, may alter the concentration of Rextol in the blood. It is important to discuss all supplements, including herbal products, with a healthcare provider.

Q: How long does Rextol stay in your system?

A: The elimination half-life, which measures how long it takes for the concentration of the drug to decrease by half, is typically 4 to 6 hours in healthy individuals. For patients with Chronic Kidney Disease, this half-life is longer, averaging about 17 hours.

Q: What happens if I accidentally miss a dose of Rextol?

A: Official patient information provides standard guidance for missed doses, which includes taking the dose as soon as remembered unless it is close to the next scheduled dose. Specific instructions for missed doses should always be reviewed according to the official product leaflet or discussed with a healthcare provider.

Q: What are some serious but rare side effects of Rextol?

A: Documented serious adverse reactions include severe hypercalcemia, sepsis, pneumonia, and rare hypersensitivity reactions such as angioedema (swelling of the face or throat).

Q: Why do doctors prescribe Rextol instead of other options sometimes?

A: Rextol is designed as a Selective Vitamin D Receptor Activator. Its mechanism selectively targets PTH suppression in the parathyroid glands. This selective action is intended to reduce the stimulation of calcium and phosphate absorption in the intestine compared to some older Vitamin D derivatives.

Q: What is the expected timeline for seeing the full benefit of Rextol?

A: Clinical trials typically monitored patients over a period of 24 weeks to assess the full response. The final PTH target and the timeline for achieving it are determined based on the patient's ongoing physiological response, tracked via the required blood test monitoring.

Q: Does Rextol require regular blood tests or monitoring?

A: Yes. Official guidelines mandate the frequent monitoring of blood markers, specifically serum calcium, phosphorus, and Parathyroid Hormone (PTH) levels. This monitoring is required, especially during the initial dosing phase and following any dose changes.

How should Rextol be stored and disposed of?

Rextol should be stored in its original container at room temperature, away from excessive heat, moisture, and direct light. Do not store this medication in the bathroom medicine cabinet, as the heat and humidity can reduce its effectiveness. Always ensure the medication is kept out of the sight and reach of children and pets to prevent accidental ingestion or misuse.

When Rextol is no longer needed or has expired, it is important to dispose of it safely. The preferred method for disposal is using a community drug take-back program or an authorized collection kiosk, which can often be found at local pharmacies or law enforcement agencies.

If a take-back option is not available and Rextol is not on a government-issued flush list, the drug can be disposed of in the household trash. To do this, mix the medicine (without crushing tablets or capsules) with an undesirable substance, such as dirt, cat litter, or used coffee grounds. Place this mixture into a sealed bag or container, and then discard it in the trash. Before discarding the empty original container, scratch out all personal information on the prescription label to protect privacy.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rextol found in:

A-Z Index: